Sugi Predict

Sugi Predict / Compounds / SCHEMBL7181680

SCHEMBL7181680

SCHEMBL7181680

CC(C)(C)P(=O)(C(=O)c1c(C(F)(F)F)cccc1C(F)(F)F)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 1/20 0.40
▸ TSHR P16473 2/20 0.39
▸ GAA P10253 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ ACP3 P15309 1/20 0.37
▸ TAS2R14 Q9NYV8 1/20 0.37
▸ PTGS1 P23219 1/20 0.36
▸ KCNK3 O14649 1/20 0.36
▸ KCNK9 Q9NPC2 1/20 0.36
▸ TYK2 P29597 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ PKM P14618 1/20 0.35
▸ POLQ O75417 1/20 0.35
▸ MRGPRX4 Q96LA9 1/20 0.35
▸ NFKB1 P19838 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ RBP4 P02753 1/20 0.34
▸ MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7175792 0.81 KCNK3 (0.40) NPSR1GAALMNAACP3TAS2R14
SCHEMBL7182268 0.80 TSHR (0.42) NPSR1TSHRGAAMEN1ALDH1A1
SCHEMBL7183498 0.78 TSHR (0.41) NPSR1TSHRGAAMEN1ALDH1A1
SCHEMBL7187317 0.78 GAA (0.41) NPSR1TSHRGAALMNAACP3
SCHEMBL7183928 0.78 ACP3 (0.39) NPSR1GAALMNAACP3TAS2R14
SCHEMBL7181415 0.77 TAS2R14 (0.41) NPSR1GAALMNAACP3TAS2R14
SCHEMBL7175290 0.77 ALDH1A1 (0.39) NPSR1GAALMNAACP3TAS2R14
SCHEMBL7174810 0.76 CA12 (0.50) TSHRGAAMEN1ALDH1A1KMT2A
SCHEMBL7184553 0.75 F2R (0.41) TSHRGAALMNAKCNK3KCNK9
SCHEMBL7185586 0.75 NPSR1 (0.41) NPSR1TSHRGAALMNAKCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 NPSR1 2669/4885TSHR 984/4885GAA 4753/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 NPSR1 3007/4885TSHR 1273/4885GAA 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.